T0	Outcomes 228 246	antitumor activity
T1	Outcomes 251 257	safety
T2	Outcomes 813 838	Grades 3 and 4 toxicities
T3	Outcomes 888 899	neutropenia
T4	Outcomes 907 914	fatigue
T5	Outcomes 925 935	neuropathy
T6	Outcomes 949 981	ixabepilone arm, and neutropenia
T7	Outcomes 989 1008	febrile neutropenia
T8	Outcomes 1015 1022	fatigue
T9	Outcomes 1029 1039	neuropathy
T10	Outcomes 1050 1060	thrombosis
T11	Outcomes 1123 1148	prostate-specific antigen
T12	Outcomes 1363 1380	partial responses
T13	Outcomes 1538 1583	Time to prostate-specific antigen progression
T14	Outcomes 1790 1804	well tolerated
T15	Outcomes 1813 1831	antitumor activity